<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<article xml:lang="KO" article-type="research-article">

<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Korean J Urol</journal-id>
<journal-id journal-id-type="publisher-id">KJU</journal-id>
<journal-title>Korean Journal of Urology</journal-title>
<issn pub-type="ppub">2005-6737</issn>
<issn pub-type="epub">2005-6745</issn>
<publisher>
<publisher-name>The Korean Urological Association</publisher-name>
</publisher>
</journal-meta>

<article-meta>

<article-id pub-id-type="doi">10.4111/kju.2009.50.8.797</article-id>

<article-categories>
<subj-group>
<subject>Original Article</subject>
<subj-group>
<subject>Basic and Translational Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Protective Effect of Hyaluronic Acid on Cyclophosphamide-Induced Cystitis in Rats</article-title>
</title-group>

<contrib-group>

<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jung Won</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Youn Wha</given-names>
</name>
<xref ref-type="aff" rid="A2">1</xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Huh</surname>
<given-names>Jung Sik</given-names>
</name>
<xref ref-type="aff" rid="A3">2</xref>
</contrib>

<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lee</surname>
<given-names>Sun-Ju</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

</contrib-group>

<aff id="A1">Department of Urology, School of Medicine, Kyung Hee University, Seoul, Korea.</aff>
<aff id="A2"><label>1</label>Department of Pathology, School of Medicine, Kyung Hee University, Seoul, Korea.</aff>
<aff id="A3"><label>2</label>Department of Urology, School of Medicine, Cheju National University, Jeju, Korea.</aff>

<author-notes>
<corresp>
Correspondence to: Sun-Ju Lee. Department of Urology, School of Medicine, Kyung Hee University, 1, Hoegi-dong, Dongdaemun-gu, Seoul 130-702, Korea. TEL: 02-958-8535, FAX: 02-959-6048, <email>sjlee@khu.ac.kr</email>
</corresp>
</author-notes>

<pub-date pub-type="ppub">
<month>08</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>08</month>
<year>2009</year>
</pub-date>
<volume>50</volume>
<issue>8</issue>
<fpage>797</fpage>
<lpage>804</lpage>
<history>
<date date-type="received">
<day>02</day>
<month>04</month>
<year>2009</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>07</month>
<year>2009</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; The Korean Urological Association, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
</permissions>

<abstract>
<sec>
<title>Purpose</title>
<p>We investigated the effect and duration of hyaluronic acid (HA) on the bladder of rats with cyclophosphamide (CYP)-induced cystitis.</p>
</sec>
<sec>
<title>Materials and Methods</title>
<p>CYP (250 mg/kg) was injected intraperitoneally in female Sprague-Dawley rats to induce cystitis. HA (0.5&#x0025;) was instilled intravesically. First, the rats were separated into 2 groups for urodynamic study (CYP group, CYP+HA group), and we assessed the inter-contraction interval, maximal voiding pressure (MVP), and pressure threshold of the 2 groups. Second, the rats were separated into 3 groups to assess the duration of effect of HA (CYP group; HA-1 group: HA was instilled 1 day before injection of CYP; HA-3 group: HA was instilled 3 days before injection of CYP), and we assessed the voiding interval for 7 days after confining the rats in metabolic cages.</p>
</sec>
<sec>
<title>Results</title>
<p>The inter-contraction interval of the CYP+HA group (236.0&#x00B1;18.3 min) was significantly longer than that of the CYP group (178.0&#x00B1;13.4 min; p&#x003C;0.03), but the MVPs of both groups did not differ significantly (32.3&#x00B1;1.2 vs. 34.0&#x00B1;2.4 cmH<sub>2</sub>O, respectively; p=0.56). The pressure threshold of the CYP+HA group (9.9&#x00B1;0.5 cmH<sub>2</sub>O) was significantly longer than that of the CYP group (13.2&#x00B1;0.7 cmH<sub>2</sub>O; p=0.002). The voiding interval decreased in each of the 3 groups according to the time after cystitis had been induced. The voiding interval was maximally decreased on the second day and returned to the pre-CYP injection level on the fifth day in each group. There was a significant difference in voiding interval among the 3 groups on the second day (p&#x003C;0.05). There was no significant difference between the CYP+HA-1 and CYP+HA-3 groups on the second day (p&#x003E;0.05).</p>
</sec>
<sec>
<title>Conclusions</title>
<p>HA has an effect of increasing the voiding interval in rats with CYP-induced cystitis, and the duration of effect is concluded to be 5 days.</p>
</sec>
</abstract>

<kwd-group>
<kwd>Hyaluronic acid</kwd>
<kwd>Cyclophosphamide</kwd>
<kwd>Cystitis</kwd>
</kwd-group>

</article-meta>
</front>

<back>

<ref-list>

 <ref id="B1">
    <label>1</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Moldwin</surname>
          <given-names>RM</given-names>
        </name>
        <name>
          <surname>Sant</surname>
          <given-names>GR</given-names>
        </name>
      </person-group>
      <article-title>Interstitial cystitis: a pathophysiology and treatment update</article-title>
      <source>Clin Obstet Gynecol</source>
      <year>2002</year>
      <volume>45</volume>
      <fpage>259</fpage>
      <lpage>272</lpage>
    </nlm-citation>
  </ref>

  <ref id="B2">
    <label>2</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Nickel</surname>
          <given-names>JC</given-names>
        </name>
        <name>
          <surname>Emerson</surname>
          <given-names>L</given-names>
        </name>
        <name>
          <surname>Cornish</surname>
          <given-names>J</given-names>
        </name>
      </person-group>
      <article-title>The bladder mucus (glycosaminoglycan) layer in interstitial cystitis</article-title>
      <source>J Urol</source>
      <year>1993</year>
      <volume>149</volume>
      <fpage>716</fpage>
      <lpage>718</lpage>
    </nlm-citation>
  </ref>

  <ref id="B3">
    <label>3</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Spanos</surname>
          <given-names>C</given-names>
        </name>
        <name>
          <surname>Pang</surname>
          <given-names>X</given-names>
        </name>
        <name>
          <surname>Ligris</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Letourneau</surname>
          <given-names>R</given-names>
        </name>
        <name>
          <surname>Alferes</surname>
          <given-names>L</given-names>
        </name>
        <name>
          <surname>Alexacos</surname>
          <given-names>N</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Stress-induced bladder mast cell activation: implications for interstitial cystitis</article-title>
      <source>J Urol</source>
      <year>1997</year>
      <volume>157</volume>
      <fpage>669</fpage>
      <lpage>672</lpage>
    </nlm-citation>
  </ref>

  <ref id="B4">
    <label>4</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Bouchelouche</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Nordling</surname>
          <given-names>J</given-names>
        </name>
      </person-group>
      <article-title>Recent developments in the management of interstitial cystitis</article-title>
      <source>Curr Opin Urol</source>
      <year>2003</year>
      <volume>13</volume>
      <fpage>309</fpage>
      <lpage>313</lpage>
    </nlm-citation>
  </ref>

  <ref id="B5">
    <label>5</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Boucher</surname>
          <given-names>WS</given-names>
        </name>
        <name>
          <surname>Letourneau</surname>
          <given-names>R</given-names>
        </name>
        <name>
          <surname>Huang</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Kempuraj</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Green</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Sant</surname>
          <given-names>GR</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress</article-title>
      <source>J Urol</source>
      <year>2002</year>
      <volume>167</volume>
      <fpage>380</fpage>
      <lpage>384</lpage>
    </nlm-citation>
  </ref>

  <ref id="B6">
    <label>6</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Oberpenning</surname>
          <given-names>F</given-names>
        </name>
        <name>
          <surname>van Ophoven</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Hertle</surname>
          <given-names>L</given-names>
        </name>
      </person-group>
      <article-title>Interstitial cystitis: an update</article-title>
      <source>Curr Opin Urol</source>
      <year>2002</year>
      <volume>12</volume>
      <fpage>321</fpage>
      <lpage>332</lpage>
    </nlm-citation>
  </ref>

  <ref id="B7">
    <label>7</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Morales</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Emerson</surname>
          <given-names>L</given-names>
        </name>
        <name>
          <surname>Nickel</surname>
          <given-names>JC</given-names>
        </name>
        <name>
          <surname>Lundie</surname>
          <given-names>M</given-names>
        </name>
      </person-group>
      <article-title>Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis</article-title>
      <source>J Urol</source>
      <year>1996</year>
      <volume>156</volume>
      <fpage>45</fpage>
      <lpage>48</lpage>
    </nlm-citation>
  </ref>

  <ref id="B8">
    <label>8</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Porru</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Campus</surname>
          <given-names>G</given-names>
        </name>
        <name>
          <surname>Tudino</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Valdes</surname>
          <given-names>E</given-names>
        </name>
        <name>
          <surname>Vespa</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Scarpa</surname>
          <given-names>RM</given-names>
        </name>
        <etal/>
      </person-group>
      <article-title>Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid</article-title>
      <source>Urol Int</source>
      <year>1997</year>
      <volume>59</volume>
      <fpage>26</fpage>
      <lpage>29</lpage>
    </nlm-citation>
  </ref>

  <ref id="B9">
    <label>9</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Constantinides</surname>
          <given-names>C</given-names>
        </name>
        <name>
          <surname>Manousakas</surname>
          <given-names>T</given-names>
        </name>
        <name>
          <surname>Nikolopoulos</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Stanitsas</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Haritopoulos</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Giannopoulos</surname>
          <given-names>A</given-names>
        </name>
      </person-group>
      <article-title>Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study</article-title>
      <source>BJU Int</source>
      <year>2004</year>
      <volume>93</volume>
      <fpage>1262</fpage>
      <lpage>1266</lpage>
    </nlm-citation>
  </ref>

  <ref id="B10">
    <label>10</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Kyker</surname>
          <given-names>KD</given-names>
        </name>
        <name>
          <surname>Coffman</surname>
          <given-names>J</given-names>
        </name>
        <name>
          <surname>Hurst</surname>
          <given-names>RE</given-names>
        </name>
      </person-group>
      <article-title>Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder</article-title>
      <source>BMC Urol</source>
      <year>2005</year>
      <volume>5</volume>
      <fpage>4</fpage>
    </nlm-citation>
  </ref>

  <ref id="B11">
    <label>11</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Takahashi</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Takeuchi</surname>
          <given-names>J</given-names>
        </name>
        <name>
          <surname>Takahashi</surname>
          <given-names>T</given-names>
        </name>
        <name>
          <surname>Miyauchi</surname>
          <given-names>S</given-names>
        </name>
        <name>
          <surname>Horie</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Uchiyama</surname>
          <given-names>Y</given-names>
        </name>
      </person-group>
      <article-title>Effects of sodium hyaluronate on epithelial healing of the vesical mucosa and vesical fibrosis in rabbits with acetic acid induced cystitis</article-title>
      <source>J Urol</source>
      <year>2001</year>
      <volume>166</volume>
      <fpage>710</fpage>
      <lpage>713</lpage>
    </nlm-citation>
  </ref>

  <ref id="B12">
    <label>12</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Cox</surname>
          <given-names>PJ</given-names>
        </name>
      </person-group>
      <article-title>Cyclophosphamide cystitis--identification of acrolein as the causative agent</article-title>
      <source>Biochem Pharmacol</source>
      <year>1979</year>
      <volume>28</volume>
      <fpage>2045</fpage>
      <lpage>2049</lpage>
    </nlm-citation>
  </ref>

  <ref id="B13">
    <label>13</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Hu</surname>
          <given-names>VY</given-names>
        </name>
        <name>
          <surname>Malley</surname>
          <given-names>S</given-names>
        </name>
        <name>
          <surname>Dattilio</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Folsom</surname>
          <given-names>JB</given-names>
        </name>
        <name>
          <surname>Zvara</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Vizzard</surname>
          <given-names>MA</given-names>
        </name>
      </person-group>
      <article-title>COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat</article-title>
      <source>Am J Physiol Regul Integr Comp Physiol</source>
      <year>2003</year>
      <volume>284</volume>
      <fpage>R574</fpage>
      <lpage>R585</lpage>
    </nlm-citation>
  </ref>

  <ref id="B14">
    <label>14</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Lanteri-Minet</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Bon</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>de Pommery</surname>
          <given-names>J</given-names>
        </name>
        <name>
          <surname>Michiels</surname>
          <given-names>JF</given-names>
        </name>
        <name>
          <surname>Menetrey</surname>
          <given-names>D</given-names>
        </name>
      </person-group>
      <article-title>Cyclophosphamide cystitis as a model of visceral pain in rats: model elaboration and spinal structures involved as revealed by the expression of c-Fos and Krox-24 proteins</article-title>
      <source>Exp Brain Res</source>
      <year>1995</year>
      <volume>105</volume>
      <fpage>220</fpage>
      <lpage>232</lpage>
    </nlm-citation>
  </ref>

  <ref id="B15">
    <label>15</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Bon</surname>
          <given-names>K</given-names>
        </name>
        <name>
          <surname>Lichtensteiger</surname>
          <given-names>CA</given-names>
        </name>
        <name>
          <surname>Wilson</surname>
          <given-names>SG</given-names>
        </name>
        <name>
          <surname>Mogil</surname>
          <given-names>JS</given-names>
        </name>
      </person-group>
      <article-title>Characterization of cyclophosphamide cystitis, a model of visceral and referred pain, in the mouse: species and strain differences</article-title>
      <source>J Urol</source>
      <year>2003</year>
      <volume>170</volume>
      <fpage>1008</fpage>
      <lpage>1012</lpage>
    </nlm-citation>
  </ref>

  <ref id="B16">
    <label>16</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Boucher</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Meen</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Codron</surname>
          <given-names>JP</given-names>
        </name>
        <name>
          <surname>Coudore</surname>
          <given-names>F</given-names>
        </name>
        <name>
          <surname>Kemeny</surname>
          <given-names>JL</given-names>
        </name>
        <name>
          <surname>Eschalier</surname>
          <given-names>A</given-names>
        </name>
      </person-group>
      <article-title>Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain</article-title>
      <source>J Urol</source>
      <year>2000</year>
      <volume>164</volume>
      <fpage>203</fpage>
      <lpage>208</lpage>
    </nlm-citation>
  </ref>

</ref-list>

</back>

<floats-wrap>

<fig position="float" id="F1">
<label>Fig. 1</label>
<caption>
  <p>(A) Inter-contraction interval (ICI) after instillation of cyclophosphamide (CYP). ICI of CYP+hyaluronic acid intravesical instillation (HA) group was significantly longer than the ICI of CYP group (p=0.03)<sup>a</sup>. (B) Maximal voiding pressure (MVP) after instillation of cyclophosphamide. There was no significant difference of MVP between CYP group and HA+CYP group (p=0.56)<sup>b</sup>. (C) Pressure threshold (PT) after instillation of cyclophosphamide. There was significant difference of PT between the HA+CYP group and the CYP group (p=0.002)<sup>c</sup>. No. of each animal group (CYP, CYP+HA)=11, NS: not significant.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kju-50-797-g001" alt-version="no"></graphic>
</fig>

<fig position="float" id="F2">
<label>Fig. 2</label>
<caption>
  <p>Voiding interval (VI) changes after intraperitoneal injection of cyclophosphamide (CYP), checked in the metabolic cage. Voiding interval between pre-CYP injection and each 0-8, 9-24, 48, 72 hour group was decreased significantly (<sup>a</sup>p&#x003C;0.05), however, 96, 120 hour group was not decreased significantly (<sup>b</sup>p&#x003E;0.05, paired t-test) in CYP, hyaluronic acid intravesical instillation (HA)-1, and HA-3 group. On the second day after CYP injection, the VI of the CYP group was significantly shorter than HA-1 group (n=6) and HA-3 group (n=6) (<sup>c</sup>p&#x003C;0.05), however, there was no difference between HA-1 and HA-3 group in VI. There was no significant difference in VI between the HA-3 group and the CYP group after the third day (p&#x003E;0.05). HA-1: hyaluronic acid intravesical instillation a day before CYP intraperitoneal injection, HA-3: hyaluronic acid intravesical instillation 3 days before CYP intraperitoneal injection.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kju-50-797-g002" alt-version="no"></graphic>
</fig>

<fig position="float" id="F3">
<label>Fig. 3</label>
<caption>
  <p>(A, B) Control group: normal urothelium in rat bladder. (C, D) Cyclophosphamide (CYP) group (n=11): bladder 1 day after injection of CYP. Totally ulcerated urothelium with marked edema in the lamina propria. (E, F) CYP+hyaluronic acid intravesical instillation (HA) group (n=11): bladder 1 day after injection of cyclophosphamide. Focally denuded urothelium with focal edema and hemorrhage in the lamina propria (H&#x0026;E stain, A, C, E &#x00D7;40; B, D, F &#x00D7;200).</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kju-50-797-g003" alt-version="no"></graphic>
</fig>

<fig position="float" id="F4">
<label>Fig. 4</label>
<caption>
  <p>Photomicrographs of bladder 7 days after injection of cyclophosphamide (CYP). After injection, voiding intervals of rats were checked for 5 days in the metabolic cage. One week after injection, changes in the bladders were confirmed by biopsy. (A, B) CYP group (n=6): hyperplastic changes in the urothelium and severe hemorrhages in the lamina propria and muscle layer. (C, D) hyaluronic acid intravesical instillation (HA)-1 group (n=6): hyperplastic changes in the urothelium and focal infiltration of neutrophils (less than 10/HPF) and lymphocytes (less than 10/HPF) in the lamina propria. (E, F) HA-3 group (n=6): hyperplastic changes in the urothelium and diffuse neutrophilic (more than 50/HPF) and lymphocytic (more than 100/HPF) infiltration in the lamina propria (H&#x0026;E stain, A, C, E &#x00D7;40; B, D, F &#x00D7;200). HPF: high power field (count under &#x00D7;400).</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kju-50-797-g004" alt-version="no"></graphic>
</fig>

<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption>
  <p>Changes in the voiding interval (VI) after intraperitoneal injection of cyclophosphamide in the 3 groups (CYP, HA-1, HA-3)</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kju-50-797-i001" alt-version="no"></graphic>
<table-wrap-foot>
<fn>
  <p>CYP: cyclophosphamide, HA-1: hyaluronic acid intravesical instillation a day before CYP intraperitoneal injection, HA-3: hyaluronic acid intravesicalinstillation 3 days before CYP intraperitoneal injection, PRE: VI before CYP intraperitoneal injection as a control. Each VI represents Mean&#x00B1;SE, <sup>a</sup>: performed by Duncan multivariated analysis (CYP vs. HA-1 and CYP vs. HA-2 have a significant difference, however, HA-1 vs. HA-3 has no significant difference)</p>
</fn>
</table-wrap-foot>
</table-wrap>

</floats-wrap>

</article>